Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules

H. Parmar, R. H. Phillips, G. Rustin, S. L. Lightman, A. V. Schally

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


Forty-one patients with advanced ovarian cancer (FIGO stage III or IV) who had relapsed following conventional treatment were treated with long acting depot preparation of D-Trp-6-LH-RH once a month. There were no exclusion criteria and patients of any age or performance status were eligible. Thirty patients continued to progress following therapy. Twenty-six patients died within the first 16 weeks from onset of therapy. Five patients remained stable (SD) on D-Trp-6-LH-RH with no change in tumor size. Six patients had evidence of clinical and/or radiological partial remission (PR) where the tumor size decreased by more than 50%. The remissions in the responding patients were maintained for a mean duration of 10 months (range 6-18 months). Thus 11 patients (6 PR + 5 SD) have had remission or stabilization of disease which has been clinically worthwile. Clinical benefit of therapy with microcapsules of slow-release D-Trp-6-LH-RH in about 26% of patients is highly encouraging. Treatment with D-Trp-6-LH-RH offers an important non-toxic alternative in patients who do not tolerate chemotherapy or who have progressive disease following chemotherapy.

Original languageEnglish (US)
Pages (from-to)531-538
Number of pages8
JournalBiomedicine and Pharmacotherapy
Issue number8
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules'. Together they form a unique fingerprint.

Cite this